Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Nov 04, 2013 7:30am EST

Can-Fite Executes Confidentiality Agreements with Pharmaceutical and Biotechnology Companies with Respect to Potential CF101 Commercialization Negotiations

Oct 25, 2013 7:00am EDT

Can-Fite BioPharma Successfully Concludes $6,000,000 Public Offering With an Over-Subscription of 300%

Oct 22, 2013 3:10pm EDT

Can-Fite BioPharma Announces Clinical and Corporate Developments for Near-Term Events

Oct 15, 2013 7:00am EDT

Can-Fite BioPharma's CF101 Drug Selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence

Oct 10, 2013 7:00am EDT

Can-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece

Oct 02, 2013 7:00am EDT

Can-Fite's Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum

Sep 23, 2013 7:00am EDT

Can-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com

Sep 12, 2013 8:19am EDT

Can-Fite's Level II ADRs Commence Trading on the U.S. OTC Markets

Sep 03, 2013 1:38pm EDT

Can-Fite to Present at Rodman & Renshaw Global Investment Conference on September 9, 2013

Aug 28, 2013 11:12am EDT

Can-Fite to Initiate a Phase II Study With CF102 in 130 Patients With Advanced Liver Cancer

  • arrow_back
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2023 Can-Fite All Rights Reserved

BrandWiz - Branding